Healthcare / BiotechnologyLSE
$0.20
+0.01 (+5.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-614610.00 · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-86.4%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-652586.0 · FCF $-614610.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2022 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | — | — | — | $50000.00 |
| Net Income | $-652586.00 | $-652586.00 | $-3.6M | $-1.1M |
| EBITDA | $-631942.00 | $-631942.00 | $-477187.00 | $-1.2M |
| EPS | -0.00 | -0.00 | -0.00 | -0.00 |
| Gross Margin | — | — | — | 96.6% |
| Operating Margin | — | — | — | -2540.5% |
| Net Margin | — | — | — | -2218.0% |
| Balance Sheet | ||||
| Current Ratio | 0.52 | 0.52 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-614610.00 | $-614610.00 | $-331883.00 | $-1.3M |
| Returns | ||||
| ROE | -86.4% | -86.4% | -508.9% | -23.4% |
| Valuation | ||||
| P/B | 440.04 | 440.04 | 60.48 | 129.47 |
| Growth & Yield | ||||
| EPS Growth | 91.5% | 91.5% | -142.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+94.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.00
Residual
+94.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.